Market capitalization | $2.43b |
Enterprise Value | $3.81b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.99 |
P/S ratio (TTM) P/S ratio | 1.27 |
P/B ratio (TTM) P/B ratio | 0.73 |
Revenue growth (TTM) Revenue growth | 17.62% |
Revenue (TTM) Revenue | $1.91b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
11 Analysts have issued a Colfax Corporation forecast:
11 Analysts have issued a Colfax Corporation forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,914 1,914 |
18%
18%
|
|
Gross Profit | 946 946 |
18%
18%
|
|
EBITDA | 217 217 |
13%
13%
|
EBIT (Operating Income) EBIT | -34 -34 |
131%
131%
|
Net Profit | -106 -106 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Colfax Corp. operates as a diversified technology company that provides orthopedic care and fabrication technology products and services to customers. The firm operates its business through the following segments: Medical Technology; and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices with a broad range of products used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures, and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Annapolis Junction, MD.
Head office | United States |
CEO | Matthew Trerotola |
Employees | 6,550 |
Founded | 1995 |
Website | www.enovis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.